The FDA has approved Lipfendra, the first PCSK9 inhibitor available as a daily pill, giving patients with severe high cholesterol a noninvasive alternative to injections. The drug, made by Merck, cleared the agency on July 16, 2026 for treating hypercholesterolemia and heterozygous familial hypercholesterolemia.
The approval hands patients with inherited high cholesterol a treatment that matches the potency of injectable PCSK9 inhibitors without the needles, refrigeration, or clinic visits. It also arrives for a population that has long struggled to reach cholesterol targets on statins alone.
How Lipfendra Works
Lipfendra’s active ingredient, enlicitide, targets the PCSK9 protein produced by the liver. PCSK9 normally binds to LDL receptors on liver cells and marks them for destruction, leaving fewer receptors available to pull LDL cholesterol — the so-called “bad cholesterol” — out of the bloodstream. By blocking PCSK9, the drug preserves those receptors so the liver keeps clearing LDL.
Nieca Goldberg, MD, a board-certified cardiologist and clinical associate professor at NYU Grossman School of Medicine, explained the mechanism: “PCSK9 inhibitors lower LDL, or ‘bad,’ cholesterol by blocking the PCSK9 protein. Normally, PCSK9 breaks down LDL receptors in the liver. By preventing that breakdown, the medication allows more LDL receptors to remain available and helps the liver clear LDL cholesterol from the bloodstream.”
Daniel Atkinson, MBBS, Clinical Lead at Treated.com, described how the drug physically interferes with PCSK9. The active ingredient “works by identifying floating PCSK9 proteins in your liver. When it ‘finds’ them, it binds to them, acting like a cap that covers its docking site,” he said. “Because the PCSK9 protein is physically blocked by the drug, it’s no longer able to attach to your liver’s LDL receptors, preventing your liver from prematurely destroying them.”
Trial Evidence Behind the Approval
The FDA’s decision rests on two randomized, double-blind, placebo-controlled trials run by Merck: CORALreef Lipids and CORALreef HeFH. Together they enrolled 3,207 adults with severe high cholesterol, both with and without familial hypercholesterolemia, who were already taking the maximum tolerated dose of statins.
In those trials, the oral PCSK9 inhibitor lowered LDL cholesterol by approximately 56% to 59%, according to Goldberg. That reduction is on top of whatever patients were already achieving with statins, making Lipfendra an add-on therapy rather than a replacement for first-line treatment.
The approved dosing is 20 milligrams taken once daily, used alongside dietary changes and physical activity. The FDA explicitly tied the indication to lifestyle interventions, not standalone use.
Why Familial Hypercholesterolemia Matters
Heterozygous familial hypercholesterolemia is an inherited form of high cholesterol driven by genetic factors rather than diet. It is more difficult to manage than lifestyle-related hypercholesterolemia and, if untreated, leads to heart attacks and heart disease — often at younger ages than the general population.
Existing options for this group have included lipoprotein apheresis, a procedure that filters fatty molecules from the blood and replaces it with healthy blood, along with statins, ezetimibe, bempedoic acid, and injectable PCSK9 inhibitors. Apheresis is invasive and logistically demanding. Injectable PCSK9 drugs require refrigerated storage and dosing every two to four weeks, or twice yearly for Leqvio.
Lipfendra collapses that convenience gap. “Lipfendra (enlicitide) bridges the gap between the convenience of a daily pill and the efficacy of an injectable,” Atkinson said.
How It Compares With Existing Drugs
Statins remain the first-line treatment for high cholesterol. They work inside liver cells to block cholesterol production and lower LDL by roughly 35% to 50%, Goldberg noted. Ezetimibe blocks cholesterol absorption in the intestine and reduces LDL by 15% to 20%. Bempedoic acid inhibits liver cholesterol production and cuts LDL by up to 28%.
Lipfendra’s 56% to 59% LDL reduction puts it well above those oral alternatives and in the same range as injectable PCSK9 inhibitors. “When compared with other non-statin pills like ezetimibe or bempedoic acid, the big difference is in efficacy,” Atkinson said. The drug also offers a different side-effect profile, which may matter for patients who cannot tolerate statin-induced muscle pain.
For patients already on injectable PCSK9 inhibitors, the trade-off is largely convenience. Repatha and Praluent require self-injections every 2 to 4 weeks, and Leqvio is given twice a year. All three require refrigerated storage. A daily pill removes those barriers, potentially improving adherence.
What Happens Next
Lipfendra’s approval reshapes the treatment ladder for familial hypercholesterolemia. Cardiologists now have a potent oral option to reach LDL targets without escalating to injections or apheresis. Expect prescribing patterns to shift as payers weigh coverage and real-world adherence data emerges.
Watch for post-marketing studies on long-term safety and outcomes, particularly cardiovascular event reduction rather than LDL reduction alone. Pricing and insurance formulary placement will determine how quickly the drug reaches patients who currently rely on injections. Broader access to a daily PCSK9 pill could also expand screening for familial hypercholesterolemia, since a simpler treatment may encourage earlier diagnosis of this underdetected genetic condition.
— Aisha Mensah, health desk, AXO News